Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10051767HBVENSG00000142627.13protein_codingEPHA2NoNo1969P29317
TVIS20069265HPVENSG00000142627.13protein_codingEPHA2NoNo1969P29317
TVIS20064798HPVENSG00000142627.13protein_codingEPHA2NoNo1969P29317
TVIS20016949HPVENSG00000142627.13protein_codingEPHA2NoNo1969P29317
TVIS20019559HPVENSG00000142627.13protein_codingEPHA2NoNo1969P29317
TVIS44024403HTLV-1ENSG00000142627.13protein_codingEPHA2NoNo1969P29317
TCGA Plot Options
Drug Information
GeneEPHA2
DrugBank IDDB01254
Drug NameDasatinib
Target IDBE0000841
UniProt IDP29317
Regulation Typeantagonist
PubMed IDs20072833; 18420784
CitationsLindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7.@@Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FY, McCann B, Galbraith S, Reitberg DP, He K, Barros A Jr, Blackwood-Chirchir A, Humphreys WG, Iyer RA: Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008 Jul;36(7):1357-64. doi: 10.1124/dmd.107.018267. Epub 2008 Apr 17.
GroupsApproved; Investigational
Direct ClassificationAromatic anilides
SMILESCC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
PathwaysDasatinib Inhibition of BCR-ABL
PharmGKBPA162372878
ChEMBLCHEMBL1421